Cyclic AMP-phosphodiesterases inhibitor improves sodium excretion in rats with cirrhosis and ascites

Liver International

Volumn 25, Issue 2, 2005, Pages 403-409

  Ahloulay, Mina ^a   Bankir, Lise ^b   Lugnier, Claire ^c   Le Bec, Alain ^c   Poirel, Odile ^a   Moreau, Richard ^a   Lebrec, Didier ^a  

^a BEAUJON HOSPITAL   (France)

^b INSTITUT DU FER À MOULIN   (France)

^c CNRS   (France)

Author keywords

Cyclic AMP; Glomerular filtration rate; Phosphate; Proximal reabsorption; Sodium retention

Indexed keywords

CYCLIC AMP; CYCLIC AMP PHOSPHODIESTERASE; PHOSPHATE; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; SODIUM;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CONTROLLED STUDY; DRUG INFUSION; DRUG MECHANISM; ENZYME ACTIVITY; IN VITRO STUDY; KIDNEY CLEARANCE; KIDNEY CORTEX; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER CIRRHOSIS; MALE; NATRIURESIS; NONHUMAN; NUCLEOTIDE METABOLISM; PATHOGENESIS; PROTEIN FUNCTION; RAT; SODIUM EXCRETION;

ANALYSIS OF VARIANCE; ANIMALS; ASCITES; CYCLIC AMP; DISEASE MODELS, ANIMAL; GLOMERULAR FILTRATION RATE; INFUSIONS, INTRAVENOUS; KIDNEY FUNCTION TESTS; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; PHOSPHODIESTERASE INHIBITORS; PROBABILITY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES; ROLIPRAM; SENSITIVITY AND SPECIFICITY;

EID: 17044429863     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01034.x     Document Type: Article

References (37)

1. Epstein M. Clinical disorders of renal function. In: Epstein M, ed. The Kidney in Liver Disease, 4th edn. Philadelphia: Hanley & Belfus, 1996; 1-178.
2. Epstein M. Hepatorenal syndrome: emerging perspectives of pathophysiology and therapy. J Am Soc Nephrol 1994; 4: 1735-53.
3. Pena J C. Renal and extra-renal mechanisms of sodium and water retention in cirrhosis with ascites. Rev Invest Clin 1995; 47: 63-79.
4. Girgrah N, Liu P, Collier J, Blendis L, Wong F. Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis. Gut 2000; 46: 114-20.
5. Wong F, Sniderman K, Blendis L. The renal sympathetic and renin-angiotensin response to lower body negative pressure in well-compensated cirrhosis. Gastroenterology 1998; 115: 397-405.
6. Ackerman Z, Karmeli F, Amir G, Rachmilewitz D. Renal vasoactive mediator generation in portal hypertensive and bile duct ligated rats. J Hepatol 1996; 24: 478-86. 7 Angeli P, Jimenez W, Arroyo V, MacKenzie H S, Zhang P L, Claria J, et al. Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology 1994; 20: 948-54.
7. Angeli P, Jimenez W, Veggian R, Fasolato S, Volpin R, MacHenzie H S, et al. Increased activity of guanosine 3′-5′-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites. Hepatology 2000; 31: 304-10.
8. Gines P, Tito L, Arroyo V, Llach J, Salmeron J M, Gines A, et al. Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. Gastroenterology 1992; 102: 280-6.
9. Ni S, Cheng Y, Cao L, Gardner D G, Humphreys M H. Mechanisms contributing to renal resistance to atrial natriuretic peptide in rats with common bile-duct ligation. J Am Soc Nephrol 1996; 7: 2110-8.
10. Valdivieso A. The kidney in chronic liver disease: circulatory abnormalities, renal sodium handling and role of natriuretic peptides. Biol Res 1998; 31: 291-304.
11. Epstein M. Renal sodium handling in liver disease. In: Epstein M, ed. The Kidney in Liver Disease, 4th edn. Philadelphia: Hanley & Belfus, 1996; 1-32.
12. Wong F, Bomzon A, Allard J, Liu P, Blendis L. Effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics and sodium homoeostasis in cirrhotic patients with refractory ascites. Clin Sci 1999; 96: 467-74.
13. Aperia A, Holtbäck U, Syren M L, Svensson L B, Fryckstedt J, Greengard P. Activation/deactivation of renal Na+, K+ -ATPase: a final common pathway for regulation of natriuresis. FASEB J 1994; 8: 436-9.
14. Helmle-Kolb C, Montrose M H, Stange G, Murer H. Regulation of Na+/H+ exchange in opossum kidney cells by parathryroid hormone, cyclic AMP and phorbol esters. Pflugers Arch 1990; 415: 461-70.
15. Weinman E J, Steplock D, Tate K, Hall R A, Spurney R F, Shenolikar S. Structure-function of recombinant Na/H exchanger regulatory factor (NHE-RF). J Clin Invest 1998; 101: 2199-206.
16. Ahloulay M, Dechaux M, Hassler C, Bouby N, Bankir L. Cyclic AMP is a hepatorenal link influencing natriuresis and contributing to glucagon-induced hyperfiltration in rats. J Clin Invest 1996; 98: 2251-8.
17. Bankir L, Martin H, Dechaux M, Ahloulay M. Plasma cAMP: a hepatorenal link influencing proximal reabsorption and renal hemodynamics? Kidney Int 1997; 51: S50-6.
18. Bankir L, Ahloulay M, Devreotes P N, Parent C A. Extracellular cAMP inhibits proximal reabsorption: are plasma membrane cAMP receptors involved? Am J Physiol Renal Physiol 2002; 282: F376-92.
19. Caregaro L, Angeli P, Merlo A, Menon F, Rondana M, Merkel C, et al. Tubular handling of sodium and phosphate in non-ascitic liver cirrhosis. Scand J Clin Lab Invest 1987; 47: 247-51.
20. Kontouras J, Billing B H, Scheuer P J. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984; 65: 305-11.
21. Sato N, Asai K, Okumura S, Takagi G, Shannon R P, Fujita-Yamaguchi Y, et al. Mechanisms of desensitization to a PDE inhibitor (milrinone) in counscious dogs with heart failure. Am J Physiol 1999; 276: H1699-705.
22. Bradford M M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
23. Dousa T P. Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int 1999; 55: 29-62.
24. Keravis T M, Wells J N, Hardman J G. Cyclic nucleotide phosphodiesterase activities from pig coronary arteries. Lack of interconvertibility of major forms. Biochem Biophys Acta 1980; 613: 116-29.
25. Fuhr J, Kaczmarczyk J, Krüttgen C D. Eine einfache colorimetrisch Methode zur Inulinbestimmung für Nieren-Clearance-Untersuchungen bei Stoffwechselgesunden und Diabetikekrn. Klin Wochenschr 1955; 33: 729-30.
26. Thompson W J. Cyclic nucleotide phosphodiesterases: Pharmacology, biochemistry and function. Pharmacol Ther 1991; 51: 13-33.
27. Lindgren S, Andersson K E. Effects of selective phosphodiesterase inhibitiors on isolated coronary, lung and renal arteries from man and rat. Acta Physiol Scand 1991; 142: 3267-70.
28. Beavo J A, Conti M, Heaslip R J. Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol 1994; 46: 399-405.
29. Nicholson C D, Challiss R A J, Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 1991; 12: 19-27.
30. Yoshida I, Takeda S, Homma S, Kusano E, Asano Y. Localization of low-KM cAMP phosphodiesterase in rat nephron segments. Kidney Blood Press Res 1997; 20: 307-11.
31. Tanahashi M, Hara S, Yoshida M, Suzuki-Kusaba M, Hisa H, Satoh S. Effects of rolipram and cilostamide on renal functions and cyclic AMP release in anesthetized dogs. Pharmacol Exp Ther 1999; 289: 1533-38.
32. Coffey A K, O'Sullivan D J, Homma S, Douse T P, Valtin H. Induction of intramembranous particle clusters in mice with nephrogenic diabetes insipidus. Am J Physiol 1991; 261: F640-6.
33. Balakrishnan V S, Coles G A, Williams J D. Effects of intravenous adenosine on renal function in healthy human subjects. Am J Physiol 1996; 271: F374-81.
34. Yagil Y. The effects of adenosine on water and sodium excretion. J Pharmacol Exp Ther 1994; 268: 826-35.
35. Hall J E, Granger J P. Adenosine alters glomerular filtration control by angiotensin II. Am J Physiol 1986; 250: F917-23.
36. Hasegawa M, Yamada S, Hirayama C. Fasting plasma caffeine level in cirrhotic patients: relationship to plasma levels of catecholamines and renin activity. Hepatology 1989; 10: 973-7.
37. Stanley A J, Forrest E H, Dabos K, Bouchier I A D, Hayes P C. Natriurectic effect of an adenosine-1 receptor antagosnist in cirrhotic patients with ascites. Gastroenterology 1998; 115: 406-11.